TITLE:
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

CONDITION:
HIV Infections

INTERVENTION:
Atazanavir/ Stavidine / Lamivudine

SUMMARY:

      The purpose of this study is to find out if 300 mg of ATV plus 100 mg of ritonavir (RTV)
      works as well as 400 mg of ATV alone as part of a regimen with stavudine XR and lamivudine
      to slow or stop the progression of HIV infection in patients who have never used anti-HIV
      drugs.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Signed Informed Consent

          -  HIV RNA greater than or equal 200 copies/mL at screening

          -  18 years old or older

          -  Must use barrier contraception

          -  Women of child-bearing potential must have a negative serum or urine pregnancy test
             within 72 hours before beginning to take the study medications

        Exclusion Criteria:

          -  Unable or unwilling to use acceptable method of birth control for the entire study
             period including 8 weeks after the study

          -  Women using oral contraceptives, pregnant or breastfeeding women

          -  Women who have a positive pregnancy test on enrollment or before beginning to take
             the study medications

          -  People who have a life expectancy of greater than 12 months

          -  Newly diagnosed HIV-related OI or any medical condition requiring acute therapy at
             the time of enrollment

          -  Any antiretroviral therapy within 30 days prior to screening

          -  Any prior antiretroviral therapy (greater than 30 days of NRTI and/or greater than 7
             days of non-nucleoside reverse-transcriptase inhibitor (NNRTI) or protease inhibitor
             therapies)

          -  Any of the following conditions: Cushings Syndrome, Gilbert's Syndrome, untreated
             hypothyroidism or hyperthyroidism, suspected primary (acute) HIV infection,
             obstructive liver disease, proven or suspected acute hepatitis in the 30 days prior
             to study entry, Intractable diarrhea (at greater than 6 loose stools per day for at
             least 78 consecutive days) within 30 days prior to study entry, history of
             hemophilia, history of acute or chronic pancreatitis, presence of cardiomyopathy (due
             to any cause) or any significant cardiovascular disease, such as unstable ischemic
             heart disease

          -  Active alcohol or substance abuse

          -  History or signs and symptoms of bilateral peripheral neuropathy greater than grade 2
             at the time of screening

          -  Previous therapy with myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or
             cytotoxic potential within 3 months of study start or the expected need for such
             therapy or therapy with methadone or ribavirin/interferons or treatment with
             neurotoxic drugs or drugs that affect CYP3A4

          -  Inability to swallow capsules
      
